Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of GSK MMRV versus ProQuad with concomitant hepatitis A and pneumococcal vaccines in children 12-14 months old
2017-000454-18Phase 2
- Sponsor
- GSK
- Start
- Jul 2017
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in measles, mumps, rubella and 1 more comparing GSK MMRV + HAV + PCV with ProQuad + HAV + PCV (2 arms). Primary endpoint: Seroresponse for antibodies to varicella-zoster virus.
02
Drugs
GSK208136varicella virus vaccine
03
Conditions
measlesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2017-000454-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000454-18.